Navigation Links
Otto Warburg Medal for Alexander Varshavsky
Date:4/2/2012

Mosbach, Germany, April 2, 2012 Biochemist and geneticist Alexander Varshavsky (California Institute of Technology, USA), who was born in Moscow and has lived in the USA since 1977, has been awarded the Otto Warburg Medal of the German Society for Biochemistry and Molecular Biology (GBM). That medal is considered to be the highest German award for biochemists and molecular biologists.

By means of genetic research carried out with yeast and cell cultures of higher organisms, Alexander Varshavsky has made a decisive contribution to discovering the importance of the ubiquitin-dependent intracellular protein degradation, which plays a central role in many regulatory processes such as, for instance, in the cell cycle, in malignant transformation, in the regulation of inflammation, immune response, and many other biological processes.

Elsevier, one of the world-leading providers of scientific, technical and medical information products and services, and its flagship title Biochimica et Biophysica Acta (BBA) are proud to be the exclusive sponsors of the prize money of 25,000 euros.

Alexander Varshavsky was born in Moscow, Russia, where he studied chemistry and obtained his PhD in biochemistry. In 1977 he emigrated to the United States and has worked initially at the Massachusetts Institute of Technology (MIT). In 1992, his laboratory moved to the California Institute of Technology (Caltech) in Pasadena.

The field of ubiquitin and regulated protein degradation was created In the 1980s, with the Varshavsky laboratory discovering the first and major biological functions of the ubiquitin system, the first degradation signals in short-lived proteins, and cloning the first ubiquitin ligases. Ubiquitylation marks proteins for degradation by the 26S proteasome. Specific malfunctions in the ubiquitin system play major roles in many human diseases, including cancer and neurodegeneration syndromes.

"Alexander Varshavsky's
'/>"/>

Contact: Dr. Anke Lischeid
lischeid@gbm-online.de
49-696-605-6712
Elsevier
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nearly a century later, new findings support Warburg theory of cancer
2. WHOIs John Waterbury receives NAS Gilbert Morgan Smith Medal
3. Weather deserves medal for clean air during 2008 Olympics
4. NYU mathematician Varadhan named recipient of National Medal of Science
5. National Medal of Science for University of Utah chemist
6. Professor Cyrus Cooper awarded the Heberden Medal of the British Society for Rheumatology
7. Inaugural Herbert A. Fleisch ESCEO-IOF Medal is awarded to Professor Gerard Karsenty
8. Genetic studies of human evolution win researcher 2011 Gani Medal
9. NIMHs Dr. Mortimer Mishkin to be awarded National Medal of Science
10. Einstein researcher receives American Cancer Society Medal of Honor
11. Salk Institute Medals to be awarded to Robert Roeder and Irwin Jacobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... gradual extinction of cold-loving species, and the European land ... from the University of Kassel in Germany and the ... that human-induced temperature increases over a 40-year period in ... the near extinction of the local land leech Xerobdella ...
... have long known that the human body runs like clockwork, ... of light and darkness. Now a team of researchers is ... activity, which could allow them to predict optimal timing for ... solar day and relieve psychosocial stress. In short, ...
... showing that dog-walking in bushland significantly reduces bird ... against the practice in sensitive bushland and conservation ... the ecological impacts of dog-walking have remained subjective ... But the first clear evidence that birds ...
Cached Biology News:Role reversal as humans suck life out of leeches 2Researchers developing device to predict proper light exposure for human health 2Researchers developing device to predict proper light exposure for human health 3A dog in the hand scares birds in the bush 2
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 , - Guests Will ... , Staying healthy in these stressful ... Attitude Health Retreats early in 2009 may provide,participants with the ... A key component of the retreat ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , ... it received a Staff Determination Letter (the "Letter") from ... the staff of Nasdaq,s Listing Qualifications Department determined, using ... the Company,s American Depository Shares ("ADRs") would be delisted ...
... web based CTMS (Clinical Trial Management System), has ... deployed visit reports, site payments, sponsor portal and ... project will include integration to our electronic data ... as other innovative functional changes to the system ...
Cached Biology Technology:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 3